CY1123698T1 - Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων - Google Patents

Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων

Info

Publication number
CY1123698T1
CY1123698T1 CY20201101139T CY201101139T CY1123698T1 CY 1123698 T1 CY1123698 T1 CY 1123698T1 CY 20201101139 T CY20201101139 T CY 20201101139T CY 201101139 T CY201101139 T CY 201101139T CY 1123698 T1 CY1123698 T1 CY 1123698T1
Authority
CY
Cyprus
Prior art keywords
enrichment
tumor cells
circulating tumor
wbc depletion
wbc
Prior art date
Application number
CY20201101139T
Other languages
English (en)
Inventor
Galla Chandra Rao
Brad Foulk
Denis Smirnov
Karl Nielsen
Original Assignee
Menarini Silicon Biosystems S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Silicon Biosystems S.P.A. filed Critical Menarini Silicon Biosystems S.P.A.
Publication of CY1123698T1 publication Critical patent/CY1123698T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η αποκαλυπτόμενη εφεύρεση αφορά μεθόδους και κιτ για την απομάκρυνση λευκών αιμοσφαιρίων από δείγματα εμπλουτισμένων σπάνιων κυττάρων.
CY20201101139T 2013-03-15 2020-12-02 Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων CY1123698T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787611P 2013-03-15 2013-03-15
PCT/US2014/027701 WO2014152758A1 (en) 2013-03-15 2014-03-14 Enrichment of circulating tumor cells by depleting white blood cells

Publications (1)

Publication Number Publication Date
CY1123698T1 true CY1123698T1 (el) 2022-03-24

Family

ID=50631046

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101139T CY1123698T1 (el) 2013-03-15 2020-12-02 Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων

Country Status (20)

Country Link
US (2) US9823238B2 (el)
EP (1) EP2972359B1 (el)
JP (1) JP6563379B2 (el)
CN (1) CN105026934A (el)
AU (1) AU2014239168A1 (el)
BR (1) BR112015022962A2 (el)
CA (1) CA2906900A1 (el)
CY (1) CY1123698T1 (el)
DK (1) DK2972359T3 (el)
ES (1) ES2846224T3 (el)
HK (2) HK1216442A1 (el)
HR (1) HRP20201907T1 (el)
HU (1) HUE052519T2 (el)
LT (1) LT2972359T (el)
MX (1) MX365713B (el)
PL (1) PL2972359T3 (el)
PT (1) PT2972359T (el)
RS (1) RS61052B1 (el)
SI (1) SI2972359T1 (el)
WO (1) WO2014152758A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108061804B (zh) * 2016-11-09 2020-05-12 北京大学人民医院 用于诊断子宫内膜异位症的生物标志物
CN109991410B (zh) * 2017-12-29 2022-07-05 上海白泽医学检验所有限公司 一种含抗cd45单抗的组合物及其使用方法
JP7494460B2 (ja) 2018-11-02 2024-06-04 東ソー株式会社 細胞に結合可能な担体の製造方法
CN109439732B (zh) * 2018-12-25 2024-04-12 迈迪速能医学技术（天津）有限公司 一种用于三维无创肿瘤早筛的试剂盒
US11890616B2 (en) 2019-03-26 2024-02-06 The Curators Of The University Of Missouri Microfluidic device for capture of micrometer scale objects and methods of using the device
KR102346111B1 (ko) * 2020-02-07 2022-01-03 주식회사 싸이토딕스 Ctc 분리용 마그네틱 비드 및 이를 이용한 ctc 분리방법
KR20230101794A (ko) * 2020-09-02 2023-07-06 메나리니 실리콘 바이오시스템스 에스.피.에이. 샘플을 취급하기 위한 시스템, 키트, 방법, 및 공정

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658132B2 (en) * 1989-11-13 1995-04-06 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
AU760560B2 (en) 1998-02-12 2003-05-15 Board Of Regents, The University Of Texas System Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA2279476C (en) * 1998-07-31 2011-09-27 Stemcell Technologies Inc. Novel antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions
US7364921B1 (en) * 1999-01-06 2008-04-29 University Of Medicine And Dentistry Of New Jersey Method and apparatus for separating biological materials and other substances
WO2001014591A1 (en) * 1999-08-21 2001-03-01 Fox John S High sensitivity biomolecule detection with magnetic particles
CN1871517A (zh) 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
US7901950B2 (en) 2005-08-12 2011-03-08 Veridex, Llc Method for assessing disease states by profile analysis of isolated circulating endothelial cells
US8889361B2 (en) * 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
WO2009070392A1 (en) 2007-11-27 2009-06-04 Veridex, Llc Automated enumeration and characterization of circulating melanoma cells in blood
US20090191535A1 (en) * 2007-12-22 2009-07-30 Mark Carle Connelly Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
CN101469310B (zh) 2007-12-28 2014-03-19 北京百奥科生物技术有限公司 从生物学样品富集靶细胞的方法及除去白细胞的方法
US8569077B2 (en) 2008-05-19 2013-10-29 Veridex, Llc Imaging of immunomagnetically enriched rare cells
WO2011063416A2 (en) * 2009-11-23 2011-05-26 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
WO2012011113A2 (en) * 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
CN108375676B (zh) 2011-07-21 2022-01-07 詹森诊断器材有限责任公司 从血液中捕获和检测循环多发性骨髓瘤的测定法
WO2013142186A1 (en) * 2012-03-21 2013-09-26 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
US20140011685A1 (en) 2012-07-03 2014-01-09 Yixin Wang Genomic diagnostics using circulating endothelial cells

Also Published As

Publication number Publication date
EP2972359B1 (en) 2020-09-23
WO2014152758A1 (en) 2014-09-25
PT2972359T (pt) 2020-10-29
SI2972359T1 (sl) 2021-01-29
PL2972359T3 (pl) 2021-03-08
DK2972359T3 (da) 2020-11-09
US9823238B2 (en) 2017-11-21
MX2015012341A (es) 2016-06-06
CA2906900A1 (en) 2014-09-25
HK1216442A1 (zh) 2016-11-11
MX365713B (es) 2019-06-11
US10365266B2 (en) 2019-07-30
CN105026934A (zh) 2015-11-04
HRP20201907T1 (hr) 2021-01-22
AU2014239168A1 (en) 2015-10-29
JP6563379B2 (ja) 2019-08-21
ES2846224T3 (es) 2021-07-28
JP2016519286A (ja) 2016-06-30
US20140335542A1 (en) 2014-11-13
LT2972359T (lt) 2020-12-10
US20180045712A1 (en) 2018-02-15
HK1219776A1 (zh) 2017-04-13
BR112015022962A2 (pt) 2017-07-18
RS61052B1 (sr) 2020-12-31
EP2972359A1 (en) 2016-01-20
HUE052519T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
CY1123698T1 (el) Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων
EA202193044A2 (ru) Способы лечения таупатии
EA201500818A1 (ru) Антитела к cd47, не вызывающие истощение тромбоцитов и красных кровяных телец, а также способы их применения
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201890754A1 (ru) Соединения и способы их применения
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
PL2986735T3 (pl) Sposób określania składu ilościowego komórek krwi w próbce
EA201791624A1 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
CR20150066A (es) 2,3-benzodiacepinas
CY1118694T1 (el) Μεθοδοι διαχωρισμου σωματιδιων χρησιμοποιωντας μια συσκευη με ενα στοιχειο διαχωρισμου με διακριση μεγεθους που εχει μια επιμηκη αιχμη
EA201590997A1 (ru) Соединения и способы их применения
EA201492101A1 (ru) Антитела против fcrn
EA201592203A1 (ru) Способы лечения таупатии
BR112015021189A2 (pt) métodos de banco de células de alta densidade
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
EA201600003A1 (ru) КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
TR201909632T4 (tr) Nmda antagonisti ön ilaçları.
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CL2013000681A1 (es) Metodo para lixiviar menas de cobre que comprende primera y segunda etapa de lixiviacion usando solucion conteniendo yoduro e ion de hierro (iii).
EA201891540A1 (ru) Наноэлектрод для определения ионов cu(ii) и способ получения и применения наноэлектрода
MX2015017413A (es) Metodos para analizar composiciones de cisteamina.